Patent intelligence · US
US 11096954
Bisphosphocin gel formulations and uses thereof
Bisphosphocin gel formulations and uses thereof
Patent details — US 11096954
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 24, 2021
- Expiration
- Aug 19, 2041
- Applicant
- Lakewood Amedex, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/7072, A61K47/10, A61K47/34
Quick answer
US 11096954 (Bisphosphocin gel formulations and uses thereof) is held by Lakewood Amedex, Inc.. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lakewood Amedex, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/7072, A61K47/10, A61K47/34, A61K9/0014, A61K9/06
More from Lakewood Amedex, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12156883
Bisphosphocin gel formulations and uses thereof
granted -
US 12054509
Antimicrobial compounds, compositions, and uses thereof
granted -
US 12030908
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11795192
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11377468
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11123357
Methods and compositions for treating oral mucositis
granted -
US 10981943
Antimicrobial compounds, compositions, and uses thereof
granted
Frequently asked questions
What is US patent 11096954?
US 11096954 (Bisphosphocin gel formulations and uses thereof) is held by Lakewood Amedex, Inc.. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11096954?
Lakewood Amedex, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 11096954 expire?
Our index shows an expiration date of Aug 19, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.